ABANZA was granted FDA 510(k) clearance for QuadLock, a knotless, bidirectional tension-adjustable fixation system for ACL reconstruction.
QuadLock is designed to securely fixate sutures and tapes, helping surgeons fine-tune graft tension and maintain stability across several graft configurations commonly used in ACL procedures, including quadriceps tendon, quadrupled semitendinosus/gracilis, and bone–patellar tendon–bone (BTB).
In biomechanical testing under high-demand cyclic loading, QuadLock demonstrated market-leading control of cyclic displacement (less than 0.5 mm)—a 500%+ improvement compared to the 3–6 mm reported for conventional fixation methods such as cortical buttons and interference screws. QuadLock also achieved a pullout strength of >1,000 N, combining high fixation strength with minimal displacement. Avoiding loss of tension under repeated loading is critical in early recovery, when fixation stability directly influences the restoration of functional joint stability.
“QuadLock reflects our focus on practical innovation—giving surgeons adjustability, control, and confidence when fixation performance matters most, especially as today’s patient population continues to evolve and traditional fixations are increasingly challenged,” said Juan Abascal, Chief Executive Officer of ABANZA. “This clearance strengthens our U.S. roadmap and supports our broader platform strategy to advance soft-tissue repair with solutions that emphasize reproducible technique and stable fixation under demanding conditions.”
ABANZA was granted FDA 510(k) clearance for QuadLock, a knotless, bidirectional tension-adjustable fixation system for ACL reconstruction.
QuadLock is designed to securely fixate sutures and tapes, helping surgeons fine-tune graft tension and maintain stability across several graft configurations commonly used in ACL procedures, including...
ABANZA was granted FDA 510(k) clearance for QuadLock, a knotless, bidirectional tension-adjustable fixation system for ACL reconstruction.
QuadLock is designed to securely fixate sutures and tapes, helping surgeons fine-tune graft tension and maintain stability across several graft configurations commonly used in ACL procedures, including quadriceps tendon, quadrupled semitendinosus/gracilis, and bone–patellar tendon–bone (BTB).
In biomechanical testing under high-demand cyclic loading, QuadLock demonstrated market-leading control of cyclic displacement (less than 0.5 mm)—a 500%+ improvement compared to the 3–6 mm reported for conventional fixation methods such as cortical buttons and interference screws. QuadLock also achieved a pullout strength of >1,000 N, combining high fixation strength with minimal displacement. Avoiding loss of tension under repeated loading is critical in early recovery, when fixation stability directly influences the restoration of functional joint stability.
“QuadLock reflects our focus on practical innovation—giving surgeons adjustability, control, and confidence when fixation performance matters most, especially as today’s patient population continues to evolve and traditional fixations are increasingly challenged,” said Juan Abascal, Chief Executive Officer of ABANZA. “This clearance strengthens our U.S. roadmap and supports our broader platform strategy to advance soft-tissue repair with solutions that emphasize reproducible technique and stable fixation under demanding conditions.”
Copy to clipboard 
